The Mulligan Lab is currently completing treatments of the SOD1G93A mouse model of ALS with four different doses of the Hsp70 protein and hopes to have the dose response study complete by the end of March/mid-April. With positive results (hopefully), our ALS scientists and clinicians will begin to design initial clinical trials in patients.
